Chiara Tarantelli

15PUBLICATIONS
80CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsMedical molecular engineering of nucleic acids and proteinsChemotherapyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Alberto J Arribas, Francesca Guidetti, Eleonora Cannas

|Jun 26, 2025
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas.

Chiara Tarantelli, Filippo Spriano, Elisa Civanelli

|Oct 07, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

Alberto J Arribas, Sara Napoli, Eugenio Gaudio

|May 25, 2024
Thinking Outside the Box: Indirect Myc Modulation in Canine B-Cell Lymphoma.

Luca Licenziato, Eugenio Mazzone, Chiara Tarantelli

|Feb 07, 2024
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies.

Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini

|Dec 05, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.

Alberto J Arribas, Sara Napoli, Luciano Cascione

Pageof 3

Frequent Collaborators

13 joint publications

Francesco Bertoni

11 joint publications

Luciano Cascione

8 joint publications

Filippo Spriano

7 joint publications

Sara Napoli